التفاصيل البيبلوغرافية
| العنوان: |
Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin A nephropathy. |
| المؤلفون: |
Schena, Francesco P1,2 (AUTHOR) paolo.schena@uniba.it, Tripepi, Giovanni3 (AUTHOR), Rossini, Michele4 (AUTHOR), Abbrescia, Daniela I5 (AUTHOR), Manno, Carlo1 (AUTHOR) |
| المصدر: |
Clinical Kidney Journal. May2022, Vol. 15 Issue 5, p895-902. 8p. |
| مصطلحات موضوعية: |
*IGA glomerulonephritis, *SODIUM-glucose cotransporter 2 inhibitors, *SEROTHERAPY, *DISEASE risk factors, *CHRONIC kidney failure, *KIDNEY diseases |
| مستخلص: |
Background Randomized controlled trials (RCTs) have been conducted, stratifying idiopathic immunoglobulin A nephropathy (IgAN) patients based on the laboratory findings [serum creatinine, estimated glomerular filtration rate (eGFR) and daily proteinuria]. In contrast, data from kidney biopsy have been used only for clinical diagnosis. Therefore, IgAN patients with active or chronic renal lesions have been receiving the same therapy in experimental and control arms of randomized clinical trials (RCTs). Methods Our clinical study of IgAN (CLIgAN) is a multicentre, prospective, controlled and open-label RCT based on patients' stratification at the time of their kidney biopsy. We will consider, first, the type of renal lesions, followed by serum creatinine values, eGFR and proteinuria. Primary and secondary endpoints will be monitored. Then, we will determine whether personalized therapy can slow the decline of renal function and delay end-stage kidney disease. Results We will enrol 132 IgAN patients with active renal lesions (66 patients per arm) in the first RCT (ACIgAN). They will receive corticosteroids combined with renin–angiotensin system blockers (RASBs) or only RASBs. A total of 294 IgAN patients with chronic or moderate renal lesions at high or very high risk of chronic kidney disease (147 patients per arm) will be enrolled in the second RCT (CHRONIgAN), in which they will receive dapagliflozin, a sodium–glucose cotransporter 2 inhibitor, combined with RASBs, or RASBs alone. Conclusion Using this approach, we hypothesize that patients could receive personalized therapy based on renal lesions to ensure that the right drug gets to the right patient at the right time. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder